Trial Search Results

Ropinirole Controlled Release (CR) as an Adjunctive Agent in the Treatment of Major Depression

This is an 8 week study for patients who are currently taking antidepressant medication but not fully responding. Ropinirole CR would be taken in conjunction with current antidepressant medication. Patients come into the clinic once a week when starting on the medication and then once every other week for the remainder of the 8 weeks.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: GlaxoSmithKline

Stanford Investigator(s):


  • Drug: Ropinirole CR




Inclusion Criteria:

   - Age 18 to 65 years old

   - Currently experiencing major depression

   - On at least an adequate dose of fluoxetine, paroxetine, sertraline, citalopram,
   escitalopram, venlafaxine, bupropion, mirtazapine or duloxetine for at least 6 weeks
   (monotherapy). Exclusion Criteria:1. Pregnant females or females of child bearing
   years not using adequate birth control in the opinion of the investigators

   - Known sensitivity to ropinirole

   - Significant medical conditions that would preclude safe participation in the study in
   the opinion of the investigators.

   - Significant abnormalities observed in screening laboratory evaluation

Ages Eligible for Study

18 Years - 65 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jessica Hawkins
Not Recruiting